Paediatrics

Methylphenidate should be first choice ADHD drug in children, Lancet study concludes

For the short-term treatment of attention-deficit hyperactivity disorder in children, methylphenidate should be the first choice of treatment, while amphetamines should be used for adults who have the condition, according to a Lancet review.

Girl with attention deficit hyperactivity disorder

Source: Shutterstock.com

Methylphenidate should be the first-line option to treat children with attention deficit hyperactivity disorder, according to a review of the safety and efficacy of seven drugs

The preferred first-line treatment for attention-deficit hyperactivity disorder (ADHD) in children is methylphenidate, a review of the evidence has concluded[1].

The research, which looked at evidence on the safety and efficacy of seven drugs used to treat the condition, also recommended that amphetamines should be the first choice in adults who have ADHD.

However, more evidence is needed on long-term effects of the drugs, and environmental modifications and other non-pharmacological treatments should be tried first, the researchers concluded in The Lancet Psychiatry on 7 August 2018.

In a large meta-analysis and systematic review, researchers looked at evidence from 133 double-blind randomised controlled trials — including 81 trials in children — for lisdexamfetamine, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil, compared with placebo over 12 weeks of treatment.

For the short-term treatment of ADHD, all of the drugs, except modafinil in adults, were more effective than placebo but were less effective and less tolerable in adults than children and adolescents, although it was unclear why.

Current guidelines on use of the drugs are inconsistent, the researchers pointed out.

The National Institute for Health and Care Excellence (NICE) already aged five years and over and young people with ADHD, with lisdexamfetamine and atomoxetine or guanfacine recommended as second and third options.

In adults, NICE recommends methylphenidate and lisdexamfetamine as first-line treatments, but other European guidelines recommend psychostimulants as first-line options with no distinctions.

Andrea Cipriani, study lead and associate lecturer in the department of psychiatry at the University of Oxford, UK, said medication could be an important tool for ADHD and the evidence showed these were safe and effective treatments in the short term.

“It’s important to note that the data available only allows us to compare the effectiveness at 12 weeks, when we know that both children and adults can be on these medications for longer,” he added.

New research should be funded urgently to assess the long-term effects of these drugs, the researchers concluded.

Citation: The Salvadore DOI: 10.1211/PJ.2018.20205303

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Principles of Good Clinical Practice

    A one-stop source for the proper conduct of clinical trials. Essential information on clinical trial design and pharmacovigilance.

    £49.00
  • Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £47.00
  • Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00
  • Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00
  • Developing Your Prescribing Skills

    Developing Your Prescribing Skills uses case studies, mind maps and feedback from experienced prescribers. It supplies practical advice on the issues facing prescribers in all types of practice.

    £23.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • Girl with attention deficit hyperactivity disorder

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.